IL310440A - Heteroaryl compounds for treating huntington's disease - Google Patents
Heteroaryl compounds for treating huntington's diseaseInfo
- Publication number
- IL310440A IL310440A IL310440A IL31044024A IL310440A IL 310440 A IL310440 A IL 310440A IL 310440 A IL310440 A IL 310440A IL 31044024 A IL31044024 A IL 31044024A IL 310440 A IL310440 A IL 310440A
- Authority
- IL
- Israel
- Prior art keywords
- pyridazin
- pyrrolo
- triazol
- phenol
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203761P | 2021-07-30 | 2021-07-30 | |
| PCT/US2022/038870 WO2023009816A1 (en) | 2021-07-30 | 2022-07-29 | Heteroaryl compounds for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310440A true IL310440A (en) | 2024-03-01 |
Family
ID=83149486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310440A IL310440A (en) | 2021-07-30 | 2022-07-29 | Heteroaryl compounds for treating huntington's disease |
Country Status (16)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| CA3249778A1 (en) * | 2022-06-15 | 2023-12-21 | Ptc Therapeutics, Inc. | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) * | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| JP2022525417A (ja) * | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
-
2022
- 2022-07-29 CN CN202280066651.3A patent/CN118159539A/zh active Pending
- 2022-07-29 MX MX2024001417A patent/MX2024001417A/es unknown
- 2022-07-29 PE PE2024000170A patent/PE20240929A1/es unknown
- 2022-07-29 KR KR1020247003414A patent/KR20240054264A/ko active Pending
- 2022-07-29 IL IL310440A patent/IL310440A/en unknown
- 2022-07-29 JP JP2024505314A patent/JP2024528066A/ja active Pending
- 2022-07-29 CA CA3227287A patent/CA3227287A1/en active Pending
- 2022-07-29 CR CR20240043A patent/CR20240043A/es unknown
- 2022-07-29 EP EP22761694.3A patent/EP4377317A1/en active Pending
- 2022-07-29 WO PCT/US2022/038870 patent/WO2023009816A1/en not_active Ceased
- 2022-07-29 AU AU2022320725A patent/AU2022320725A1/en active Pending
- 2022-07-29 AR ARP220102027A patent/AR126612A1/es unknown
- 2022-07-29 US US18/293,349 patent/US20240336613A1/en active Pending
- 2022-08-01 TW TW111128808A patent/TW202321247A/zh unknown
-
2024
- 2024-01-29 CL CL2024000250A patent/CL2024000250A1/es unknown
- 2024-01-30 CO CONC2024/0000890A patent/CO2024000890A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240043A (es) | 2024-05-22 |
| CO2024000890A2 (es) | 2024-04-29 |
| MX2024001417A (es) | 2024-05-14 |
| EP4377317A1 (en) | 2024-06-05 |
| JP2024528066A (ja) | 2024-07-26 |
| CL2024000250A1 (es) | 2024-07-12 |
| PE20240929A1 (es) | 2024-04-30 |
| US20240336613A1 (en) | 2024-10-10 |
| AR126612A1 (es) | 2023-10-25 |
| CA3227287A1 (en) | 2023-02-02 |
| AU2022320725A1 (en) | 2024-02-22 |
| CN118159539A (zh) | 2024-06-07 |
| WO2023009816A1 (en) | 2023-02-02 |
| TW202321247A (zh) | 2023-06-01 |
| KR20240054264A (ko) | 2024-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3006294C (en) | Combinations of rapamycin and metformin for the treatment of joint and skin diseases | |
| AU2023229524A1 (en) | Combination therapy of tetracyclic quinolone analogs for treating cancer | |
| US20260097028A1 (en) | Methods of Treating Myeloproliferative Neoplasms | |
| JP2024528066A5 (cg-RX-API-DMAC10.html) | ||
| CA2736361A1 (en) | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor | |
| CN102438588A (zh) | 使用联合治疗法治疗疾病的方法 | |
| CN1777424A (zh) | 抗肿瘤联合药物 | |
| AU2005312061B2 (en) | Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof | |
| TW201922256A (zh) | 治療淋巴樣惡性疾病之方法 | |
| CA2940983A1 (en) | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer | |
| US20200131196A1 (en) | Rapamycin Analog | |
| EP2498606A1 (en) | Tivozanib and temsirolimus in combination | |
| CA2946151C (en) | Stable solid immunosuppressor composition | |
| US20250387383A1 (en) | Methods of treating myeloproliferative neoplasms | |
| US20230029336A1 (en) | Combination Therapy for Treating a Hematological Malignancy | |
| CA3155068A1 (en) | Drug combination containing tlr7 agonist | |
| EA049145B1 (ru) | Способы лечения миелопролиферативных неоплазий | |
| HK1060062B (en) | Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil |